Study to Examine the Effects of MultiStem in Ischemic Stroke

Trial ID or NCT#



not recruiting iconNOT RECRUITING


A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke. The hypothesis is that MultiStem will be safe and provide benefit following an ischemic stroke.

Official Title

Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke

Eligibility Criteria

Ages Eligible for Study: 18 Years to 83 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Male or female subjects between 18 and 83 years of age (inclusive) - Clinical diagnosis of cortical cerebral ischemic stroke - Occurrence of a moderate to moderately severe stroke
Exclusion Criteria:
  1. - Presence of a lacunar or a brainstem infarct - Reduced level of consciousness - Major neurological event such as stroke or clinically significant head trauma within 6 months of study


Nirali Vora
Nirali Vora
Stroke and vascular neurologist, General neurologist, Neurohospitalist
Clinical Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.


Neil Schwartz